Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

Old API Wind-down Ltd - Ordinary Shares > ARZ: expect strong results for year 2017, next week!
View:
Post by Royal10 on Mar 08, 2018 2:12pm

ARZ: expect strong results for year 2017, next week!

Please, read: "Our performance in the third quarter demonstrates the strength of our underlying business, with growth in the U.S. and Canada, and puts us on the path to profitability as reflected by the achievement of positive quarterly adjusted earnings before interest, taxes, depreciation and amortization for the first time as Aralez," said Adrian Adams, chief executive officer of Aralez. "We are delighted with the evolution of Zontivity , the improved outlook for the Toprol-XL franchise in the U.S. and the continued strong performance of the Canadian business. As a result of this performance, we updated our 2017 financial guidance and now expect full-year net revenue to be in the range of $95-million to $105-million."
Comment by Royal10 on Mar 09, 2018 10:26am
Nice breakout today with stronger volume. I hope that we will reach the $4.00 level in the next few days. Guidance for 2018 is for revenue between $140-million to $160-million. These numbers should attract new buyers.
Comment by Stocker46 on Mar 13, 2018 1:27pm
This company never fails to disappoint. Their revenues are good but they still haven't got their costs under control.
Comment by mjh9413 on Mar 13, 2018 1:32pm
And latest qtr and forecast say they will contine not to do so..Also proj 2108 EBITDA of $35 is compised of $26 cash interest!!!!  Yosparola OUT...so much for $80MM in revs!!! Lousy balance sheet. I bailed. One of worst investments I ever made. YUK!
Comment by Stocker46 on Mar 13, 2018 6:43pm
Likely a good decision to bail. I never got in but was tempted on a couple of occassions. I made some nice profits on Stellar (that was bought by Tribute) and even a little on Tribute but ARZ has been a disaster.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities